U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951359) titled 'A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors' on Nov. 16.

Brief Summary: This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: BIOLOGICAL: BNT3211

Intravenous infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: BioNTech SE

Disclaimer: Curated by HT Syndication....